Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

NCT01370148 is registered in ClinicalTrials.gov with Cumberland Pharmaceuticals as lead sponsor.

NCT NCT01370148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01370148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Lead sponsor
Cumberland Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2011
Completion date
February 28, 2014
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

liver disease